Alzheimer's disease, dementia, and stem cell therapy

doi:10.1186/s13287-017-0567-5

Review

. 2017 May 12;8(1):111.

doi: 10.1186/s13287-017-0567-5.

Alzheimer's disease, dementia, and stem cell therapy

Thomas Duncan¹, Michael Valenzuela²

Affiliations

¹ Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
² Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia. michael.valenzuela@sydney.edu.au.

PMID: 28494803
PMCID: PMC5427593
DOI: 10.1186/s13287-017-0567-5

Review

Alzheimer's disease, dementia, and stem cell therapy

Thomas Duncan et al. Stem Cell Res Ther. 2017.

. 2017 May 12;8(1):111.

doi: 10.1186/s13287-017-0567-5.

Authors

Thomas Duncan¹, Michael Valenzuela²

Affiliations

¹ Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia.
² Regenerative Neuroscience Group, Brain and Mind Centre & Sydney Medical School, University of Sydney, Sydney, NSW, 2050, Australia. michael.valenzuela@sydney.edu.au.

PMID: 28494803
PMCID: PMC5427593
DOI: 10.1186/s13287-017-0567-5

Abstract

Alzheimer's disease (AD) represents arguably the most significant social, economic, and medical crisis of our time. Characterized by progressive neurodegenerative pathology, AD is first and foremost a condition of neuronal and synaptic loss. Repopulation and regeneration of depleted neuronal circuitry by exogenous stem cells is therefore a rational therapeutic strategy. This review will focus on recent advances in stem cell therapies utilizing animal models of AD, as well as detailing the human clinical trials of stem cell therapies for AD that are currently undergoing development.

Keywords: Alzheimer’s disease; Embryonic stem cells; Induced pluripotent stem cells; Mesenchymal stem cells; Neural stem cells.

PubMed Disclaimer

Cited by

Microglia modulate proliferation, neurite generation and differentiation of human neural progenitor cells.
Lilienberg J, Apáti Á, Réthelyi JM, Homolya L. Lilienberg J, et al. Front Cell Dev Biol. 2022 Oct 13;10:997028. doi: 10.3389/fcell.2022.997028. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36313581 Free PMC article.
Intraluminal Farnesol and Farnesal in the Mealworm's Alimentary Canal: An Unusual Storage Site Uncovering Hidden Eukaryote Ca²⁺-Homeostasis-Dependent "Golgicrine" Activities.
De Loof A, Schoofs L. De Loof A, et al. Front Endocrinol (Lausanne). 2019 Dec 19;10:885. doi: 10.3389/fendo.2019.00885. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31920991 Free PMC article. Review.
Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy.
Yin T, Liu Y, He B, Gong B, Chu J, Gao C, Liang W, Hao M, Sun W, Zhuang J, Gao J, Yin Y. Yin T, et al. Mater Today Bio. 2023 Sep 1;22:100789. doi: 10.1016/j.mtbio.2023.100789. eCollection 2023 Oct. Mater Today Bio. 2023. PMID: 37706205 Free PMC article. Review.
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.
Staff NP, Jones DT, Singer W. Staff NP, et al. Mayo Clin Proc. 2019 May;94(5):892-905. doi: 10.1016/j.mayocp.2019.01.001. Mayo Clin Proc. 2019. PMID: 31054608 Free PMC article. Review.
Mitochondrial Dysfunction: A Key Player in Brain Aging and Diseases.
Bartman S, Coppotelli G, Ross JM. Bartman S, et al. Curr Issues Mol Biol. 2024 Mar 2;46(3):1987-2026. doi: 10.3390/cimb46030130. Curr Issues Mol Biol. 2024. PMID: 38534746 Free PMC article. Review.

See all "Cited by" articles

References

1. Alzheimers Association 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332. doi: 10.1016/j.jalz.2015.02.003. - DOI - PubMed
1. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. doi: 10.1056/NEJMoa1304839. - DOI - PMC - PubMed
1. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50. doi: 10.1056/NEJMoa1210951. - DOI - PubMed
1. Walker D, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81:412–25. doi: 10.1002/jnr.20484. - DOI - PubMed
1. Delbeuck X, Van der Linden M, Collette F. Alzheimer’s disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79–92. doi: 10.1023/A:1023832305702. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

[1] Alzheimers Association 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332. doi: 10.1016/j.jalz.2015.02.003. - DOI - PubMed

[2] Alzheimers Association 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11:332. doi: 10.1016/j.jalz.2015.02.003. - DOI - PubMed

[3] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. doi: 10.1056/NEJMoa1304839. - DOI - PMC - PubMed

[4] Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33. doi: 10.1056/NEJMoa1304839. - DOI - PMC - PubMed

[5] Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50. doi: 10.1056/NEJMoa1210951. - DOI - PubMed

[6] Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50. doi: 10.1056/NEJMoa1210951. - DOI - PubMed

[7] Walker D, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81:412–25. doi: 10.1002/jnr.20484. - DOI - PubMed

[8] Walker D, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81:412–25. doi: 10.1002/jnr.20484. - DOI - PubMed

[9] Delbeuck X, Van der Linden M, Collette F. Alzheimer’s disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79–92. doi: 10.1023/A:1023832305702. - DOI - PubMed

[10] Delbeuck X, Van der Linden M, Collette F. Alzheimer’s disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79–92. doi: 10.1023/A:1023832305702. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Alzheimer's disease, dementia, and stem cell therapy

Affiliations

Alzheimer's disease, dementia, and stem cell therapy

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical